1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.

Slides:



Advertisements
Similar presentations
Using Prognosis to Make Screening Decisions Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Hollis Day, MD, MS University of Pittsburgh.
Advertisements

1 Could there be a single European EQ tariff? Jan J.V. Busschbach, Ph.D. Former address: –iMTA, Erasmus university Present address: –Medical Psychology.
How do we achieve cost effective cancer treatments in the UK? Professor Peter Littlejohns Department of Public Health and Primary Care.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Justice and Economic Evaluation Prof. Dr. Jan Busschbach
1 Cancer: Where We Are and Where We Must Go John R. Seffrin, PhD National Chief Executive Officer American Cancer Society American Association for Cancer.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
Copyright © 2005 Brooks/Cole, a division of Thomson Learning, Inc. 6.1 Chapter Six Probability.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
EPECEPECEPECEPEC American Osteopathic Association AOA: Treating Our Family and Yours Osteopathic EPEC Osteopathic EPEC Education for Osteopathic Physicians.
Schneider Institute for Health Policy Heller Graduate School Brandeis University September by Donald S. Shepard, Ph.D. Schneider Institute for Health.
QALYs and Ethics Prof. dr. Jan van Busschbach 11.
Quality of life Assessment introduction
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
QALYs and Ethics Is there an ethical / valid alternative?
O LD A GE. W HY R ETIRE ? Reasons for Not Retiring.
1 Cost-effectiveness in Personality Disorder Dr. J.J.V. Busschbach Psychotherapeutic centre ‘De Viersprong’ –PO Box AA Halsteren
Age of Consent and Legal Ages. Mr Wilson’s ERC (Secondary 4)
Poor health as cause and consequence of unemployment: mechanisms and interventions Alex Burdorf Department of Public Health Erasmus Medical Centre in Rotterdam.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
Improving the Quality of Life for Patients with Incurable Diseases at the Terminal Stage of Illness Khatereh Hadi October, 2011.
BACKGROUND Cost-effectiveness of Psychotherapy for Cluster C Personality Disorders and the Value of Information and Implementation Djøra I. Soeteman 1,2,
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
Clear & Cole, American Corrections, 8 th Chapter 6 The Correctional Client.
General Election 2010 What the Parties Say – Health.
1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands  
Elder Mistreatment: A geriatrician’s perspective Hal H. Atkinson, MD, MS Associate Professor Department of Internal Medicine, Section on Gerontology and.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
The Future Research Agenda for Women’s Health Stacie E. Geller, Ph.D. Director, UIC Center for Research on Women and Gender and The National Center of.
Ethical issues related to alcoholism Can science help to explain them Zdenka Čebašek-Travnik.
Cost-effectiveness of psychotherapy for personality disorders Djøra Soeteman Viersprong Institute for Studies on Personality Disorders Erasmus Medical.
Module 2: Quality and Quality Measures The degree to which health services for individuals and populations increase the likelihood of desired health outcomes.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
Cancer Amanda phillips. Questions What is cancer? How do you get it? What causes it? What treats it? What are some cures? Those are all of the questions.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
11 Cost Effectiveness in Preventing Crime  Jan van Busschbach, Djøra Soeteman  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam, 
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Cost Effectiveness  Jan J.V. Busschbach, Ph.D.  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Patient centred care and vulnerability in old age: An overview of qualitative empirical research undertaken as part of a PhD Presentation for BGS Nurse.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
“A HEALTHY OUTSIDE STARTS FROM THE INSIDE” Robert Urich.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
How to weight cost effectiveness in appraisal NVTAG / CVZ course: The appraisal process, work in progress 22th of April 2009 Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
The Gender Gap: Health Care Disparities between Men and Women By Maria Psilis.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
The male sexual problems is a very wide problem around the world, it's more common than people realize. It affect around 7% of the young population in.
TOPIC 1.2, RISK. SPECIFICATIONS: RISK 1.18 Analyse and interpret quantitative data on illness and mortality rates to determine health risks (including.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
The Healthcare Funding and Delivery Challenge 25 th November 2010.
“Working towards a healthier Thanet” Dr Tony Martin, Clinical Chair, Thanet CCG.
Haley Venable Period 2. This section is explaining what exactly mental disorders are, how to recognize when someone has a mental disorder and how a mental.
The burden of disease in patients with personality disorder indicated for psychotherapy: Arguments for necessity of care Djøra Soeteman, MSc
Cervical Cancer Awareness: HPV 101
How much does the U.S. spend to treat different diseases?
Your Symptoms Matter – Prostate Cancer
The Israel Lung Cancer Foundation
Justification treatment cost
Presentation transcript:

1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy PO Box DR Rotterdam Psychotherapeutic centre 'De Viersprong’ –PO Box AA Halsteren Presentations can be found at –

2 Health Economics Comparing different allocations –Should we spent our money on »Wheel chairs »Screening for cancer »Preventing alcohol abuse –Comparing costs –Comparing outcome Relate costs to outcome –Cost per outcome

3 Car economics Should we spend our money on a –Suzuki Alto 1.0 –BMW 316 –Comparing costs –Comparing outcome Relate costs to outcome –Cost per outcome –Cost per kilometer »Suzuki Alto 1.0 »BMW 316

4 Car league table

5 Health Economics Comparing costs –Inside health care –Outside health care Comparing outcome –Life years –Quality of life »Quality Adjusted Life Years »QALYs

6 QALY league table

7 Additional arguments in car economic When people are facing the bad cost effectiveness of their own car... Denial –Validity and ad hoc arguments »My car is not on the list... »I drive more kilometres... »I drive a diesel... The use additional arguments –The sensation of driving –Beauty –Space –Prestige

8 Additional arguments in health care reimbursement If economics evaluation fails –Reimbursement of lung transplantation –No reimbursement of Viagra Denial –Debate about the validity of the health economics »lung transplantation: not all cost of screening / waiting list should be included »Viagra: preferences for sex (erectile functioning) can not be measured in QALYs –Secondly, ad hoc arguments are used »lung transplantation: it is unethical to let someone die »Viagra: erectile dysfunction in old men is not a disease

9 Ad hoc arguments represents burden of disease Severity of illness –Looking forwards »Prospective health –lung transplantation: it is unethical to let someone die »Rule of rescue »Necessity of care Faire innings –Looking backwards »Total health –Viagra: when you get older, erectile dysfunction is not longer considered a disease »You had you share of the cake »Does not apply for younger man

10 Combining “severity of illness” with “faire innings” (Elly Stolk)

11 CE-ratio by burden of disease

12 Burden of disease and prevention Severity of illness –The potential patient is not ill (yet) »Focuses on the patients that die now, not in the future »Discounting Fair innings –The future patients is still collecting his faire innings Burden of disease is not in favour of prevention –Prevention has to be more cost effective than cure

13 Can we escape the negative influence of burden of disease? Define conservative target population –Flu vaccination is to prevent mortality in elderly »Not to prevent mobility –Alcohol abuse programs is not for the common men »Low burden of disease in normal life Otherwise dilution of burden... –Explains reimburcement when media focus on victims »meningitis vaccination Different target as for cost effectiveness –Cost effectiveness: treated population –Burden of disease: main target population

14 Conclusion Cost effectiveness arguments exits next to other arguments The burden of disease argument is negative for prevention –Prevention has to be more cost effective than cure Focus burden of disease studies on those patient groups for who it really matters –To prevent the erosion of the argument